A A A A
 
Pages
Meet The Team How-Tos Our Supporters How to Participate in Precision Panc Membership Meeting Minutes Remit of Steering Committee Patient Stories Documents Working with the NHS Patient Public Engagement Meetings Governance News Clinicians Area Clinical Trials What is precision medicine? Information and Support What is Pancreatic Cancer? Current Research Our Researchers Privacy Policy Patients and Carers Contact Us About us Home
Posts
Precision-Panc Recruits Patient 250 Marking World Pancreatic Cancer Day Precision-Panc working with myTomorrows Precision-Panc Roundtable Final Report New Glasgow Cancer Assays by GPOL and Agilent Technologies Precision-Panc opens site 25! Precision-Panc Summer Newsletter Precision-Panc Recruits Patient 200! Precision-Panc Brochure Royal Bournemouth Hospital Opens Finding the right treatment for the patient CRUK animate the Precision-Panc platform CRUK / Precision-Panc Video Professor Biankin receives the Order of Australia in Queen’s Birthday Honours Precision-Panc opens its 20th Site Precision Panc Spring Newsletter Precision-Panc Opens Site 19 Recent Media Pieces Regarding 100 Patient Milestone Site 17 opens for Precision-Panc PRIMUS 002 opens Informing the Future of Genomic Medicine in Scotland Report is Published St James’s University Hospital Opens Precision-Panc Opens its 15th site Glasgow Experts Lead UK Pancreatic Cancer Research 11th site opens to PRECISION-Panc Scotsman Conferences Blogspot November is Pancreatic Cancer Awareness Month First Precision-Panc Trial Opens In Glasgow Cancer Research UK Investment Landscape of pancreatic neuroendocrine cancer Whole Genome Sequencing from EUS biopsies Upcoming Pancreas 2016 Conference Scottish Genome Partnership Announced Identification of four Pancreatic Cancer subtypes offers new treatment insight into the disease First Minister announces £4m ‘Precision Medicine Ecosystem’
Menu
 
 
Home | Team Members | David Chang
 


Department:
Head of Therapeutic Development

Institution:
Glasgow Precision Oncology Laboratory

David Chang

Head of Therapeutic Development at the Glasgow Precision Oncology Laboratory and Reader in Surgery at the University of Glasgow

Dr David Chang is a surgeon–scientist and Head of Therapeutic Development at the Glasgow Precision Oncology Laboratory (GPOL). Dr Chang is a Reader in Surgery with the University of Glasgow’s Institute of Cancer Sciences. He is also co-lead on the Precision-Panc programme. Dr Chang is Chief Investigator (CI) of the Precision-Panc Master Protocol and is Translational CI for PRIMUS 001, 002 and 004

Dr Chang specialises in the treatment of malignant pancreatic diseases and his research focus is on the development and implementation of novel therapeutic strategies for pancreatic cancer in particularly around DNA-damage response deficiency, by utilising molecular biomarkers of prognosis and therapeutic responsiveness.

Spending his early years in Taiwan before moving to Australia, where he completed his medical education in Sydney, and specialised in hepato-pancreato-biliary (HPB) (liver, pancreas, gallbladder and bile ducts) and upper gastro-intestinal surgery.

During 2007, Dr Chang also attained a Master of Surgery degree at the University of Sydney and took up a PhD in pancreatic cancer at the Garvan Institute of Medical Research in 2008.

‘With the PhD, I could see what I was researching can potentially be translated into practice within five or ten years,’ said Dr Chang. ‘There were also many collaborative projects, first within New South Wales and then the whole of Australia, as well as large international collaborative projects, like the International Cancer Genome Consortium (ICGC). What is exciting is the crossing of disciplines, going from surgery to molecular biology to genomics, to bioinformatics, clinical trials, statistics and biostatistics.’

Dr Chang was recruited to University of Glasgow in 2013 as part of an initiative to implement precision medicine in the West of Scotland and the UK. He is also an Honorary Consultant Pancreatic Surgeon at Glasgow Royal Infirmary that serves as tertiary pancreatic referral centre for the West of Scotland. His clinical research aim is to shorten the distance between the bench and the clinic to ensure meaningful and seamless translation between the two.

‘With the Precision-Panc clinical trials programme, we are seeing the translation of what we hypothesised into real-world outcomes. There are small wins, such as changing patients’ pathways, better ways of reporting CT scans and the pathology, improvements to the running of the multidisciplinary team and how soon we see the patient in the clinic or put them on treatment.’

‘But the big wins will be the practice-changing moments, such as driving the Glasgow Precision Oncology Laboratory’s Glasgow Cancer Test into the NHS, or a clinical trial result that delivers changes in practice, though that is probably a few years away.’

‘As a surgeon-scientist, I feel extremely privileged to work on pancreatic cancer on the bench and also at the bedside. I truly hope through our work that we are able to offer patients with pancreatic cancer more treatments and improve their outcomes.’

Dr Chang is also involved in Precision Promise, a Pancreatic Cancer Action Network (USA) initiative dedicated in delivering personalised treatment for patients with pancreatic cancer. He also contributes to the ICGC Accelerating Research in Genomic Oncology (ARGO) initiative, aiming to shape the future of the next-generation cancer genomic projects to ultimately realise the goals and promises of precision medicine.


© 2019 Precision Panc
Web design by Creatomatic
This site uses cookies.
Configure
 
Read our privacy policy

This site uses cookies for marketing, personalisation, and analysis purposes. You can opt out of this at any time or view our full privacy policy for more information.